How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy
Research from MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA shows the potential of a more patient-friendly dosing regimen for Stage 4 CRC/PC or locally advanced PC.
This collaboration highlights how real-world data can contribute to clinical research and can help answer pressing questions about care already taking place in clinical practice.
Key Takeaways from ASH 2022: Real-World Data Gets Down to Business
The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.
Are Pharma Companies Ready to Harness the Promises of Real-World Data?
Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting
COTA is honored to have contributed to three abstracts accepted for poster presentation at the American Society of Hematology’s 64th Annual Meeting, which cover a range of hematologic cancers. These studies focus on patient- and clinician-reported performance status in Multiple Myeloma, and real-world treatment patterns among patients with newly diagnosed Acute Myeloid Leukemia in the US.
COTA and Google Partner to Use Natural Language Processing to Harness Unstructured Data
We are excited to announce our partnership with Google Cloud to use their Natural Language Processing (NLP) technology to help us better understand the unstructured data in cancer patients’ medical records.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
Early Detection Saves Lives: A Real World Breast Cancer Story
When it comes to cancer, there are a lot of myths and misconceptions out there. But the one thing is for certain: cancer can affect anyone, at any time, and from any background. Hear from one of our own about their battle with breast cancer and how early detection helped them defeat cancer.
Real-World Evidence is Now a “True End-to-End Capability” for Life Science Companies, Says Deloitte
Deloitte’s new Real-World Evidence Survey reveals that life sciences companies are now using real-world data (RWD) and real-world evidence (RWE) throughout the product life cycle—from early discovery through commercialization.
With Tailored, Fit-for-Purpose RWD from COTA, Life Science Companies Can Drive Innovation
Innovation is the key to success in the life sciences industry. But with the vast amounts of data being generated by clinical trials and other research, it can be difficult to know where to focus your efforts. COTA’s tailored, fit-for-purpose real-world data (RWD) can help.
Patient-Centered Drug Development Leads the Way in 2022
This will be the year that patient centricity drives drug development and care delivery decisions.
